Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its Q3 earnings later this week. Experts are anticipating strong performance driven by the strong demand of Lilly's blockbuster treatments, particularly the diabetes franchise. However, there are also concerns about potential headwinds from regu